346a1fb58e
Adds complete go-to-market analysis for Signal CGM asset sale: Analysis/ - signal-cgm-segment-scoring-v1.md (3-model scoring across 7 segments) - signal-cgm-re-scored-composite-v2.md (50/30/20 composite, MA+Medicaid scope) - signal-cgm-final-ranking-leverage-v3.md (final 4-segment rank + leverage map) Assets/ - signal-cgm-pitch-v1-plain.md (plain language leave-behind) - signal-cgm-pitch-v2-professional.md (professional leave-behind) - master-summary.md (rankings, metrics, next-steps prompt) Key findings: 25.2% CGM improper payment rate; 20% net revenue loss; 63% of denied claims permanently written off; billing company #1 target for pilot; NikoHealth #1 for asset sale. Co-Authored-By: Claude Sonnet 4.6 <noreply@anthropic.com> |
||
|---|---|---|
| .. | ||
| Analysis | ||
| Assets | ||
| master-summary.md | ||